Conflict of interest statement: Conflict of interest statement The authors 
declare the following financial interests/personal relationships, which may be 
considered as potential competing interests: S.G. serves in an 
advisory/consultancy role for AstraZeneca, Bayer, Blueprint Medicines, Daiichi 
Sankyo, Deciphera Pharmaceuticals, Eli Lilly and Exelixis; has a leadership role 
in Alliance Foundation; receives licensing royalties from Wolters Kluwer Health 
and is a shareholder/stockholder of Abbott Laboratories and Allergan, and her 
institution receives research support from Bayer, Blueprint Medicines, Deciphera 
Pharmaceuticals, Novartis and Pfizer. P.C. serves in an advisory role for 
Deciphera Pharmaceuticals, Exelixis and Zailab; has received grant funding from 
Deciphera Pharmaceuticals, Exelixis, Novartis and Array and has licensing 
royalties and owns stock in ORIC. M.C.H. serves in a consultancy role for 
Blueprint Medicines, Deciphera Pharmaceuticals and Novartis; receives royalties 
from Novartis; receives grant funding from Blueprint Medicines and Deciphera 
Pharmaceuticals and has received travel, accommodations, and expenses from 
Blueprint Medicines and Deciphera Pharmaceuticals. M.v.M. serves in an 
advisory/consultancy role for Blueprint Medicines, Deciphera Pharmaceuticals and 
Exelexis and has received travel/accommodation expenses from Deciphera 
Pharmaceuticals and NCCN, and her institution has received funding from Arog, 
ASCO, Blueprint Medicines, Deciphera Pharmaceuticals, Gradalis, Genmab, Novartis 
and Solarius. R.L.J. has received honoraria and serves in an advisory role for 
Adaptimmune Therapeutics, Athenex, Bayer, Boehringer Ingelheim, Blueprint 
Medicines, Clinigen Group, Daiichi Sankyo, Deciphera Pharmaceuticals, Eisai, 
Epizyme, Immune Design, Eli Lilly, Merck, PharmaMar, UpToDate; serves in an 
advisory role for Boehringer Ingelheim and Tracon and has received funding from 
MSD. K.G. serves in an advisory role for Daiichi Sankyo and Foundation Medicine, 
and her institution has received grant funding from Deciphera Pharmaceuticals. 
J.T. serves in an advisory/consultancy role for Blueprint Medicines, Deciphera 
Pharmaceuticals, Daiichi Sankyo, Epizyme and Agios, and his institution has 
received grant funding from Advenchen, Agios, Blueprint Medicines, Deciphera 
Pharmaceuticals, and Plexxikon. H.G. institution has received grant funding from 
Daiichi Sankyo, Five Prime, Novartis, Deciphera Pharmaceuticals, Eli Lilly, 
Roche, Eisai, Debio, Boehringer Ingelheim, Pfizer, Amgen and TEVA. A.A.R. 
institution has received grant funding from Deciphera Pharmaceuticals. M.S.G. 
serves in an advisory/consultancy role for Agenus, Daiichi Sankyo, Deciphera 
Pharmaceuticals, ImaginAB, Imaging Endpoints, RedHill Biopharma, Salarius and 
Tracon, and has a leadership role in CareMission; his institution has received 
grant funding from AbbVie, Aeglea, Agenus, Amgen, Arcus, Astex, BeiGene, 
Blueprint Medicines, Bristol Meyers Squibb, Calithera, CellDex, Corcept, Clovis, 
Daiichi Sankyo, Deciphera Pharmaceuticals, Eli Lilly, Endocyte, Five Prime, 
Fujifilm Pharma, Genocea, ImaginAB, Medimmune, Merck, Neon, Plexxikon, RedHill 
Biopharma, Revolution Medicine, Roche/Genentech, Salarius, Seattle Genetics, 
Serono, Syndax, SynDevRx, Tesaro, Tolero, Tracon, and Veru, and he owns stock in 
Medelis. N.S. serves in an advisory role for Bayer, Blueprint Medicines and 
Deciphera Pharmaceuticals; has stocks in Pfizer and has received grant funding 
from Ascentage, AstraZeneca, Daiichi Sankyo, Deciphera Pharmaceuticals, GSK and 
Karyopharm. J.J. is employed by Deciphera Pharmaceuticals. J.M. is employed by 
Deciphera Pharmaceuticals and owns stock in Deciphera Pharmaceuticals. K.S. is 
employed by Deciphera Pharmaceuticals and owns stock in Alberio, Alnylam, 
AstraZeneca, Immunogen, Karyopharm, Deciphera Pharmaceuticals, and Spectrum. 
Y.S. is employed by Deciphera Pharmaceuticals. R.R-S. is employed by Deciphera 
Pharmaceuticals and owns stock in Deciphera Pharmaceuticals and Immunogen. F.J. 
serves in an advisory role for Asana, Baush Health, Cardiff Oncology, Deciphera, 
Guardant Health, Ideaya, IFM Therapeutics, Immunomet, Illumina, Jazz 
Pharmaceuticals, Novartis, PureTech Health, Sotio and Synlogic and has stocks in 
Cardiff Oncology, and his institution receives funding from Agios, Asana, 
Astellas, Astex, Bayer, Bicara, BioMed Valley Discoveries, Bioxcel, Bristol 
Myers Squibb, Deciphera, Fujifilm Pharma, Genentech, Ideaya, JS InnoPharm, Eli 
Lilly, Merck, Novartis, Novellus, Plexxikon, Proximagen, Sanofi, Sotio, 
SpringBank Pharmaceuticals, SQZ Biotechnologies, Synlogic, Synthorx and 
Symphogen.